Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2012

Open Access 01-04-2012 | Original Article

Role of the general practitioner during the active breast cancer treatment phase: an analysis of health care use

Published in: Supportive Care in Cancer | Issue 4/2012

Login to get access

Abstract

Purpose

Little is known about the actual involvement of the general practitioner (GP) during the active breast cancer treatment phase. Therefore, this study explored (disease-specific) primary health care use among women undergoing active treatment for breast cancer compared with women without breast cancer.

Methods

A total of 185 women with a first diagnosis of early-stage breast cancer between 1998 and 2007 were identified in the primary care database of the Registration Network Groningen and matched with a reference population of 548 women without breast cancer on birth year and GP.

Results

Since diagnosis, patients with breast cancer had twice as many face-to-face contacts compared with women from the reference population (median 6.0 vs 3.0/year, Mann–Whitney (M-W) test p < 0.001). The median number of drug prescriptions and referrals was also significantly higher among patients than among the reference population (11.0 vs 7.0/year, M-W test p < 0.001 and 1.0 vs 0.0/year, M-W test p < 0.001). More patients than women from the reference population had face-to-face contacts or were prescribed drugs for reasons related to breast cancer and its treatment, including gastrointestinal problems, psychological reasons and endocrine therapy.

Conclusions

During the active breast cancer treatment phase, GPs are involved in the management of treatment-related side effects and psychological symptoms, as well as in the administration of endocrine therapy. Based on the findings of this study, interventions across the primary/secondary interface can be planned to improve quality of life and other outcomes in patients undergoing breast cancer treatment.
Literature
1.
2.
Campbell NC, Macleod U, Weller D (2002) Primary care oncology: essential if high quality cancer care is to be achieved for all. Fam Pract 19:577–578PubMedCrossRef
3.
McAvoy BR (2007) General practitioners and cancer control. Med J Aust 187:115–117PubMed
4.
Grunfeld E (2005) Cancer survivorship: a challenge for primary care physicians. Br J Gen Pract 55:741–742PubMed
5.
Weller DP, Harris MF (2008) Cancer care: what role for the general practitioner? Med J Aust 189:59–60PubMed
6.
Brotzman GL, Robertson RG (1998) Role of the primary care physician after the diagnosis of cancer. The importance of the team approach. Prim Care 25:401–406PubMedCrossRef
7.
Pruthi S, Brandt KR, Degnim AC et al (2007) A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc 82:999–1012PubMedCrossRef
8.
Grunfeld E (2008) Primary care physicians and oncologists are players on the same team. J Clin Oncol 26:2246–2247PubMedCrossRef
9.
Cella D, Fallowfield LJ (2008) Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 107:167–180PubMedCrossRef
10.
Montazeri A (2008) Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 27:32PubMedCrossRef
11.
Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156–166PubMedCrossRef
12.
Pascoe SW, Neal RD, Allgar VL et al (2004) Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract 21:437–442PubMedCrossRef
13.
Grunfeld E, Earle CC (2010) The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr 2010:25–30PubMedCrossRef
14.
Macleod U, Ross S, Twelves C et al (2000) Primary and secondary care management of women with early breast cancer from affluent and deprived areas: retrospective review of hospital and general practice records. BMJ 320:1442–1445PubMedCrossRef
15.
Del Giudice L, Bondy SJ, Chen Z et al (2006) Physician care of cancer patients. In: Jaakkimainen L, Upshur R, Klein-Geltink JE et al (eds) Primary care in Ontario: ICES atlas. Institute for Clinical Evaluative Sciences, Toronto, pp 161–174
16.
Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21:299–304PubMedCrossRef
17.
Tate AR, Martin AG, Murray-Thomas T et al (2009) Determining the date of diagnosis—is it a simple matter? The impact of different approaches to dating diagnosis on estimates of delayed care for ovarian cancer in UK primary care. BMC Med Res Methodol 9:42PubMedCrossRef
18.
van der Veen WJ, Meyboom-de Jong B (2004) Age and gender. In: Jones R, Britten N, Culpepper L et al (eds) Oxford textbook of primary medical care. Oxford University Press, Oxford, pp 153–161
19.
Lamberts H, Wood M (1987) ICPC. International Classification of Primary Care. Oxford University Press, Oxford
20.
WHO Collaborating Centre for Drug Statistics Methodology (1999) ATC index with DDS. World Health Organisation, Oslo
21.
Hawfield A, Lovato J, Covington D et al (2006) Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol 59:250–255PubMedCrossRef
22.
Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555PubMedCrossRef
23.
Bickell NA, Weidmann J, Fei K et al (2009) Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol 27:5160–5167PubMedCrossRef
24.
Garg P, Rana F, Gupta R et al (2009) Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Breast J 15:404–408PubMedCrossRef
25.
van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC et al (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122:843–851PubMedCrossRef
26.
Allgar VL, Neal RD, Pascoe SW (2003) Cancer patients consultation patterns in primary care and levels of psychological morbidity: findings from the Health Survey for England. Psychooncology 12:736–740PubMedCrossRef
27.
Pascoe SW, Neal RD, Heywood PL et al (2008) Identifying patients with a cancer diagnosis using general practice medical records and Cancer Registry data. Fam Pract 25:215–220PubMedCrossRef
28.
Schouten LJ, Hoppener P, van den Brandt PA et al (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22:369–376PubMedCrossRef
29.
Jefford M, Baravelli C, Dudgeon P et al (2008) Tailored chemotherapy information faxed to general practitioners improves confidence in managing adverse effects and satisfaction with shared care: results from a randomized controlled trial. J Clin Oncol 26:2272–2277PubMedCrossRef
Metadata
Title
Role of the general practitioner during the active breast cancer treatment phase: an analysis of health care use
Publication date
01-04-2012
Published in
Supportive Care in Cancer / Issue 4/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1133-9

Other articles of this Issue 4/2012

Supportive Care in Cancer 4/2012 Go to the issue

Original Article

Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients

Original Article

Nutritional surveillance and weight loss in head and neck cancer patients

Original Article

UW WELL-FIT: the impact of supervised exercise programs on physical capacity and quality of life in individuals receiving treatment for cancer

Original Article

Psychological impairment in patients urgently referred for prostate and bladder cancer investigations: the role of trait emotional intelligence and perceived social support

Original Article

Relationship between hopelessness, loneliness, and perceived social support from family in Turkish patients with cancer

Original Article

Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits